162 related articles for article (PubMed ID: 31556584)
1. pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer.
Dong Y; Liao H; Fu H; Yu J; Guo Q; Wang Q; Duan Y
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38417-38428. PubMed ID: 31556584
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
Chen G; Wang Y; Xie R; Gong S
J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
[TBL] [Abstract][Full Text] [Related]
3. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
[TBL] [Abstract][Full Text] [Related]
4. Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer.
Yu H; Guo C; Feng B; Liu J; Chen X; Wang D; Teng L; Li Y; Yin Q; Zhang Z; Li Y
Theranostics; 2016; 6(1):14-27. PubMed ID: 26722370
[TBL] [Abstract][Full Text] [Related]
5. A uPAR targeted nanoplatform with an NIR laser-responsive drug release property for tri-modal imaging and synergistic photothermal-chemotherapy of triple-negative breast cancer.
Yu S; Huang G; Yuan R; Chen T
Biomater Sci; 2020 Jan; 8(2):720-738. PubMed ID: 31777866
[TBL] [Abstract][Full Text] [Related]
6. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
[TBL] [Abstract][Full Text] [Related]
7. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
8. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
9. Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy.
Saw PE; Yao H; Lin C; Tao W; Farokhzad OC; Xu X
Nano Lett; 2019 Sep; 19(9):5967-5974. PubMed ID: 31381852
[TBL] [Abstract][Full Text] [Related]
10. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking.
Huang Y; Dai X; Guan Z; Liu D; Ren L; Chen M; Zeng Z; Jiang J; Luo Y; He Y; Huang M; Zhao C
Int J Pharm; 2022 Jun; 622():121897. PubMed ID: 35690308
[TBL] [Abstract][Full Text] [Related]
11. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
[TBL] [Abstract][Full Text] [Related]
13. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
[TBL] [Abstract][Full Text] [Related]
14. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
Li C; Li T; Huang L; Yang M; Zhu G
Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
[TBL] [Abstract][Full Text] [Related]
16. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Zhou Y; Yu S; Chen D; Li H; Xu P; Yuan C; Jiang L; Huang M
Mol Pharm; 2023 Feb; 20(2):905-917. PubMed ID: 36463525
[TBL] [Abstract][Full Text] [Related]
17. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
18. Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance.
Lin YX; Wang Y; An HW; Qi B; Wang J; Wang L; Shi J; Mei L; Wang H
Nano Lett; 2019 May; 19(5):2968-2978. PubMed ID: 30924343
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
20. The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer.
Gong K; Jiao J; Xu C; Dong Y; Li D; He D; Zhao D; Yu J; Sun Y; Zhang W; Bai M; Duan Y
J Nanobiotechnology; 2021 May; 19(1):165. PubMed ID: 34059068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]